歌礼制药-B:ASC30完成IIA期患者入组 预计25年Q4读出顶线数据

东吴证券
Aug 06

的每日口服剂型减重适应症13 周IIa 期研究已经完成入组,总计125 名患者,预计将在2025 年Q4 读出顶线数据。ASC30 拥有美国和全球化合物专利保护,专利保护期至2044 年(不含专利延期)。ASC30 美国IIa 期临床顺利开展,25 年Q4 顶线数据读出:该研究是一项13 周、随机、双盲、安慰剂对照和多中心研究,适应症为肥胖或伴有至少一种体重相关合并症的超重。试验评估两种每日一次...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10